MuMicrowave catheter for the treatment of hypertension
Project Lead
Dr Pierre Qian, University of Sydney
Project Team
Dr Poornima Balaji, University of Sydney; Dr Duc Nguyen, University of Sydney; Dr Stuart Thomas, University of Sydney; Prof Aravinda Thiagalingam, University of Sydney; Prof Alistair McEwan University of Sydney; Dr Michael Barry, Western Sydney Local Health District, Dr Ian Fong, Cath Rx
Industry Partner
CathRx
Project Summary
Problem
Current renal denervation (RDN) technologies require repeated renal angiography to assess efficacy, increasing patient risk and procedure duration. Mu, a microwave catheter, faces barriers in attracting investor funding for clinical trials due to the need for clearer value proposition and competitive advantage amidst evolving RDN technologies.
Solution
To address these challenges, we propose integrating a novel venous blood flow measurement device into the Mu system. This device will provide real-time feedback on RDN efficacy, eliminating the need for repeated renal angiography and reducing patient exposure to contrast and radiation. By enhancing the Mu system with physiologically guided endpoint capabilities, we aim to de-risk the technology, secure new intellectual property (IP), attract further development funding, and enhance prospects for substantial investment required for clinical trials.
Impact
Integrating real-time venous blood flow measurement capabilities into the Mu RDN system will revolutionise the clinical workflow for treating renal denervation. This innovation promises to streamline procedures, reduce patient risks associated with traditional imaging methods, and improve overall efficiency. With validated measures of RDN efficacy readily available during procedures, Mu stands to establish itself as a leader in the evolving landscape of renal denervation technologies, potentially transforming treatment outcomes for patients with hypertension and related conditions.
